Aquestive Investor Deck Details $95M Contingent Funding Access Ahead of March 2027 Anaphylm PDUFA
AQST sits 25% above its 52-week low of $2.93.
Summary
Aquestive furnished its November 2026 investor presentation, disclosing $90.3 million in cash plus up to $95 million of approval-contingent funding from RTW and Oaktree as it heads toward the March 16, 2027 Anaphylm PDUFA date.
Key Events · Product Development and Regulatory · AQST
-
Investor Deck Furnished Under Item 7.01
The 8-K contains no transaction or operating announcement; it furnishes the November 2026 corporate presentation as Exhibit 99.1 for institutional investor meetings.
-
Approval-Contingent Funding Access Disclosed
Presentation cites $90.3 million in cash and cash equivalents as of September 30, 2026, plus potential access to $75 million under a strategic funding agreement with RTW Investments and an additional $20 million under the Oaktree Capital Management debt facility — both subject to conditions including FDA approval of Anaphylm, with no assurance either becomes available.
-
Anaphylm PDUFA Set for March 16, 2027
The deck reiterates the Class 2 resubmission timeline with a March 16, 2027 PDUFA goal date and targets ex-U.S. filings in Canada by year-end 2026 and the E.U. in Q1 2027.
-
Pipeline Revenue Estimates Restated
Company estimates potential peak annual net sales of >$1 billion for Anaphylm, >$100 million in potential annual U.S. product sales for Libervant (licensed to Eton), and >$500 million annual revenue for AQST-108 in atopic dermatitis — explicitly not revenue forecasts.
Analysis · AQST · Life Sciences
The 8-K is only a furnishing of the November 2026 investor presentation, but the deck puts hard numbers on how Aquestive funds an Anaphylm launch: $90.3 million of cash at September 30, 2026, plus up to $75 million from RTW Investments and $20 million from the Oaktree facility — both gated on FDA approval of Anaphylm. That is roughly $185 million of potential liquidity against a March 16, 2027 PDUFA goal date, which matters because the company is running a $70.8 million stockholders' deficit and the Q3 print showed revenue falling to $7.6 million. The catch is that the incremental capital is conditional, not committed: if the FDA issues another complete response letter, the funding does not arrive. The deck also frames the commercial case — >$1 billion estimated annual U.S. revenue for Anaphylm, >$100 million potential Libervant sales through Eton, and >$500 million for AQST-108 in atopic dermatitis — all company estimates, not forecasts.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AQST was trading at $3.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460M. The 52-week trading range was $2.93 to $6.85. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.